5874-75-9

Basic information

• Product Name: H-ORN(Z)-OME HCL
• Synonyms: H-ORN(Z)-OME HCL;ORNITHINE(Z)-OME HCL;N-DELTA-CARBOBENZOXY-L-ORNITHINE METHYL ESTER HYDROCHLORIDE;N-DELTA-Z-L-ORNITHINE METHYL ESTER HYDROCHLORIDE;N5-Benzyloxycarbonyl-L-Ornithine methyl ester hydrochloride;H-Orn(Z)-OMe;H-Orn(Cbz)-OMe·HCl;L-Orn(Cbz)-OMe·HCl
• CAS NO: 5874-75-9
• Molecular Formula: C₁₄H₂₀N₂O₄*ClH
• Molecular Weight: 316.78
• Mol File: 5874-75-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 138-141℃
• Appearance: /Solid
• Storage Temp.: 2-8°C
• CAS DataBase Reference: H-ORN(Z)-OME HCL(CAS DataBase Reference)
• NIST Chemistry Reference: H-ORN(Z)-OME HCL(5874-75-9)
• EPA Substance Registry System: H-ORN(Z)-OME HCL(5874-75-9)

Safety Data

• Hazardous Substances Data: 5874-75-9(Hazardous Substances Data)

Usage

General Description

H-ORN(Z)-OME HCL is a chemical compound often used in scientific research and biochemical studies. Its systematic name is L-Ornithine, N-[(phenylmethoxy)carbonyl]-, methyl ester, hydrochloride. The compound belongs to the group of amino acids and derivatives and is classified as an alkyl-aryl-or-alicyclic substituted alcohol. It's a white or off-white crystalline powder that is soluble in water. Due to its properties and characteristics, it's considered a high-quality reagent in biochemistry research. The caution is required in its handling and use due to health hazards and physical dangers.

Upstream product

• 3304-51-6 N-carboxybenzyl-L-ornithine 
• 2480-95-7 methyl (S)-5-(((benzyloxy)carbonyl)amino)-2-((tertbutoxycarbonyl)amino)pentanoate 
• 67-56-1 methanol 

Downstream Products

• 73871-01-9 Z-L-Pro-L-Val-δ-Z-L-Orn-OMe 
• 6372-23-2 N^δ-Benzyloxycarbonyl-N^α-(N^δ-benzyloxycarbonyl-N^α-formyl-L-ornithyl)-L-ornithin-hydrazid 
• 53157-90-7 tert-butoxycarbonylalanyl-N^δ-benzyloxycarbonylornithine 
• 1231734-54-5 H-Nδ-Z-Orn-OMe isocyanate 
• 2480-95-7 methyl (S)-5-(((benzyloxy)carbonyl)amino)-2-((tertbutoxycarbonyl)amino)pentanoate 
• 1372712-27-0 TmG-Orn(Z)-OMe 
• 1252809-29-2 (3S,4S)-4-[3'-(benzyloxycarbonyl)amino]propyl-4-methoxycarbonyl-3-methyl-2-oxoazetidine 
• 1252809-30-5 (3S,4S)-4-[3-(benzyloxycarbonyl)amino]propyl-1-tert-butoxycarbonyl-4-methoxycarbonyl-3-methyl-2-oxoaze4-methoxycarbonyl-3-methyl-2-oxoazetidine 
• 1252809-39-4 (3S,4S)-1-benzyl-4-(tert-butoxycarbonyl)amino-4-methoxycarbonyl-3-methyl-2-oxoazepane 
• 3588-50-9 N^α-tert.-Pentyloxycarbonyl-N^δ-benzyloxycarbonyl-L-ornithin 

Relevant articles and documents

Synthesis and Pharmacological Evaluation of Novel Arginine Analogs as Potential Inhibitors of Acetylcholine-Induced Relaxation in Rat Thoracic Aortic Rings

It is widely appreciated that the vascular endothelium is capable of modulating vascular smooth muscle tone suiting it well for its role as an important regulator of a number of diverse biological processes. Endothelial dysfunction is an early manifestation of atherothrombosis and a consequence of the established disease. Although several arginine derivatives alkylated at one of the guanidino nitrogen were found to inhibit vasorelaxation induced by acetylcholine, activity of the corresponding arginine esters is not reported. The present work was therefore designed to synthesize and evaluate series of novel arginine derivatives to obtain further insight into structure-activity relationship in this series of compounds. Present study involves assessment of activity of these novel compounds on the vascular tone of rat thoracic aorta in comparison with l-arginine analog, that is, l-nitro-arginine methyl ester (l-NAME). Results from the present study showed that full reversal of phenylephrine-mediated contraction was achieved by cumulative applications of acetylcholine (3nm-300μm), which were abolished when the aortic rings were pretreated with l-NAME (300μm). Results from the present study demonstrated that these novel arginine derivatives cause significant yet reversible reduction in acetylcholine-mediated relaxation, similar to that of l-NAME.

Inhibitors or bone reabsorption and antagonists of vitronectin receptors

Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors The present invention relates to 5-membered ring heterocycles of the formula I, in which E, F, G, W, Y and Z have the meaning given in the patent claims, to their preparation a